Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;77(8):2759-2765.
doi: 10.1007/s12070-025-05531-3. Epub 2025 May 28.

Sinonasal Cancers: Single Center Experience

Elif Sertesen Camoz  1 , Ozturk Ates  1 , Caner Kilic  2 , Fatih Goksel  3 , Ebru Atasever Akkas  3 , Ilknur Deliktas Onur  1 , Cengiz Karacin  1 , Ulku Yalcintas Arslan  1
Affiliations

Sinonasal Cancers: Single Center Experience

Elif Sertesen Camoz et al. Indian J Otolaryngol Head Neck Surg. 2025 Aug.

Abstract

To share our experience of sinonasal cancer management as a tertiary center.This is a retrospective study from a single tertiary center. The staging was performed according to the AJCC, 8th edition.A total of twenty-six patients were included in the study. The majority of the patients were male (76.9%), with the maxillary sinus as the primary tumor being predominant (80.8%), as was squamous cell histology (65.5%). T4 tumors at diagnosis accounted for 61.5% of the patients. The local recurrence rate was 23.1%. Induction chemotherapy was the initial treatment choice for 11.5% (n = 3) of the patients. Primary surgery was selected for 7.7% of the patients, and chemoradiotherapy was the treatment choice for 53.8%. The median follow-up duration was 56 months (95%CI: 29.8-82.1). The median overall survival (OS) was not reached, with 61.5% of patients remaining alive. The median disease-free survival (DFS) was not reached. Additionally, 61.5% of patients did not experience local recurrence or metastasis. Local recurrence was identified as an adverse prognostic factor for OS (NR vs 30 months, 95%CI 0.543-59.457, p = 0.037). Intracranial extension was identified as an adverse prognostic factor for DFS (NR vs. 7 months, 95%CI 0-14.321, p = 0.019).SNCs are rare and heterogeneous cancers that require a multidisciplinary management approach. Due to nonspecific symptoms, most patients are diagnosed at advanced stages. More prospective data are needed to optimize patient care.

Keywords: Diplopia; Induction chemotherapy; Maxillary sinus carcinoma; Nasal carcinoma.

PubMed Disclaimer

References

    1. Llorente JL, López F, Suárez C, Hermsen MA (2014) Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 11(8):460–472. 10.1038/nrclinonc.2014.97 - PubMed
    1. Ferrari M, Orlandi E, Bossi P (2021) Sinonasal cancers treatments: state of the art. Curr Opin Oncol 33(3):196–205. 10.1097/CCO.0000000000000726 - PMC - PubMed
    1. Castelnuovo P, Lambertoni A, Sileo G et al (2021) Critical review of multidisciplinary approaches for managing sinonasal tumors with orbital involvement. Acta Otorhinolaryngol Ital 41:76–89. 10.14639/0392-100X-suppl.1-41-2021-08 - PMC - PubMed
    1. Haddad RI, Hicks WL, Hitchcock YJ, et al. NCCN Guidelines Version 4.2024 Head and Neck Cancers Continue NCCN Guidelines Panel Disclosures.; 2024. https://www.nccn.org/home/member-
    1. Abdelmeguid AS, Teeramatwanich W, Roberts DB et al (2021) Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses. Cancer 127(11):1788–1795. 10.1002/cncr.33452 - PubMed